Science

Mar 13, 2025, 09:32

Myeloma Paper of the Day, March 13th, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Large-scale dependency and drug screens characterize the therapeutic vulnerabilities of myeloma with 1q, including synergy between MCL1 and PI3K inhibitors, possibly enabling their use at lower doses with less toxicity.”

“Large-scale dependency and drug screens characterize the therapeutic vulnerabilities of Multiple Myeloma with 1q+”

Authors: Romanos Sklavenitis-Pistofidis, Elizabeth Lightbody, Mairead Reidy, Junko Tsuji, Jean-Baptiste Alberge, Michelle Aranha, Matthew Davids, Maria Papaioannou, Gad Getz, Irene Ghobrial, Salomon Manier et al.

Myeloma Paper of the Day

More posts featuring Robert Orlowski.

blood cancer Elizabeth Lightbody Gad Getz Irene Ghobrial Jean-Baptiste Alberge Junko Tsuji Mairead Reidy Maria Papaioannou Matthew Davids Michelle Aranha MM multiple myeloma Myeloma Paper of the Day OncoDaily Oncology Robert Orlowski Romanos Sklavenitis-Pistofidis Salomon Manier

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer

We are thrilled to welcome Dr. Jasmine Kamboj to the OncoDaily Editorial Board!

Oncologist Near Me – Fedro Alessandro Peccatori: Leading Expert in Gynecological Oncology

MATTERHORN trial - FLOT plus durvalumab will become the new standard of care in the preoperative setting for gastroesophageal cancer

Special Coverage